Gary Goldenberg - Feb 24, 2022 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Chief Medical Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Feb 24, 2022
Transactions value $
$0
Form type
4
Date filed
2/25/2022, 03:36 PM
Next filing
Jul 5, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +75K $0.00 75K Feb 24, 2022 Common Stock 75K $8.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.